1. Home
  2. UAMY vs VTYX Comparison

UAMY vs VTYX Comparison

Compare UAMY & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

HOLD

Current Price

$10.47

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$13.98

Market Cap

990.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAMY
VTYX
Founded
1968
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
990.9M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
UAMY
VTYX
Price
$10.47
$13.98
Analyst Decision
Strong Buy
Hold
Analyst Count
5
7
Target Price
$7.69
$13.50
AVG Volume (30 Days)
10.0M
3.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
66.67
40.30
EPS
N/A
N/A
Revenue
$14,937,962.00
N/A
Revenue This Year
$164.09
N/A
Revenue Next Year
$218.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
71.84
N/A
52 Week Low
$1.21
$0.90
52 Week High
$19.71
$15.34

Technical Indicators

Market Signals
Indicator
UAMY
VTYX
Relative Strength Index (RSI) 64.90 71.25
Support Level $6.57 $13.89
Resistance Level $11.97 $14.07
Average True Range (ATR) 0.82 0.03
MACD 0.21 -0.12
Stochastic Oscillator 96.35 66.67

Price Performance

Historical Comparison
UAMY
VTYX

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: